Search PubMed⌕ Search

Biomedical subjects

P Mora

Publications and source records attributed to P Mora.

70 records · Page 4Linked to original sources
PubMed1981

[Broncaspin in respiratory diseases in pediatrics. Clinical contribution].

Broncaspin (guacetisal) has been administered rectally to 42 children suffering from inflammatory diseases of the upper and lower airways, most cases being complicated by bronchospasm. Treatment involving a dose of 1-2 suppositories of 0.5 g/die up to six years of age, and 2 suppositories/die after the sixth year always produced a good antipyretic and anti-cough effect. The preparation was outstanding for speed of action, local and general tolerance, and the absence of haematological, hepatic or renal side-effects. The new drug is considered to be a valuable instrument for anti-inflammatory and anti-cough treatment in acute diseases of the airways in infancy.

Aspirin↗
PubMedDate not supplied

Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short term clinical trial.

PURPOSE: To evaluate the efficacy and safety of 0.2% brimonidine eye drops given twice daily in normal tension glaucoma. PATIENTS AND METHODS: Sixteen consecutive patients fulfilling eligibility criteria (glaucomatous optic neuropathy associated with visual field defect in at least one eye, intraocular pressure (IOP) < or = 18 mmHg (average of the two highest readings of the round-the-clock curve, including one reading at midnight in supine position), no prior glaucoma therapy, angle wide open, visual acuity 20/40 or better) were enrolled in this prospective, randomized, placebo-controlled clinical trial with crossover design, lasting 30 days for each treatment phase plus 15-day washout in between. Main outcome was IOP (average of the two highest readings of the round-the-clock curve). RESULTS: Mean IOP was significantly reduced by brimonidine (from 17.1 +/- 0.7 mm Hg to 13.9 +/- 2.2 mmHg, p<0.001 (paired Student t-test)). At the end of the 30-day brimonidine phase, 4 of 16 subjects showed a > or = 30% IOP decrease over baseline. CONCLUSIONS: In the short term, 0.2% brimonidine eye drops can induce a significant IOP decrease in eyes with normal tension glaucoma.

Antihypertensive Agents↗